TrialThe Lancet. Neurology2019

Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial.

Magdy Selim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.